This invention provides compositions, compounds, and uses thereof, wherein said compounds comprise a single strand oligonucleotide that may form a short oligonucleotide hairpin or stem loop molecule with self complementary base pairing of less than 12 base pairs that bind to RIG-I and activate the RIG-I pathway.

Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

The invention relates to a new process for the purification of oligonucleotides which comprises the removal of an acid labile 5′hydroxy protecting group at the 5′-O-oligonucleotide terminus of the oligonucleotide by means of an on-column de-protection with an acid.

The invention relates to a new process for the purification of oligonucleotides which comprises the removal of an acid labile 5′hydroxy protecting group at the 5′-O-oligonucleotide terminus of the oligonucleotide by means of an on-column de-protection with an acid.

Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.

This application relates to therapeutic siRNA agents and methods of making and using the agents.

This application relates to therapeutic siRNA agents and methods of making and using the agents.

Disclosed is a method for the synthesis of a therapeutic double-stranded RNA (tdsRNA), comprising: a) synthesizing a first single-stranded RNA (first ssRNA) in a first synthesis reaction with PNPase as the only RNA polymerase; b) synthesizing a second single-stranded RNA (second ssRNA) in a second synthesis reaction with PNPase as the only RNA polymerase; and c) hybridizing the first ssRNA with the second ssRNA to form the tdsRNA; wherein step a) and step b) are performed in any order. Also disclosed is a product produced by the method.

Disclosed is a method for the synthesis of a therapeutic double-stranded RNA (tdsRNA), comprising: a) synthesizing a first single-stranded RNA (first ssRNA) in a first synthesis reaction with PNPase as the only RNA polymerase; b) synthesizing a second single-stranded RNA (second ssRNA) in a second synthesis reaction with PNPase as the only RNA polymerase; and c) hybridizing the first ssRNA with the second ssRNA to form the tdsRNA; wherein step a) and step b) are performed in any order. Also disclosed is a product produced by the method.